Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELAVL1 | Q15717 | 6/20 | 0.92 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22130699 | 0.96 | ELAVL1 (1.00) | ELAVL1MEN1KMT2AMAPTHTR6 | |
| SCHEMBL22130674 | 0.85 | ELAVL1 (0.71) | ELAVL1MEN1KMT2AALDH1A1NPC1 | |
| Dimethylamine SCHEMBL21222569 | 0.84 | ELAVL1 (0.90) | ELAVL1HTR6 | |
| SCHEMBL19737490 | 0.84 | ELAVL1 (1.00) | ELAVL1MEN1KMT2AMAPTHTR6 | |
| SCHEMBL22130695 | 0.81 | ELAVL1 (0.76) | ELAVL1KMT2AMAPTHTR6ALDH1A1 | |
| SCHEMBL22130714 | 0.81 | ELAVL1 (0.83) | ELAVL1MEN1KMT2AHTR6SMN1; SMN2 | |
| SCHEMBL22130697 | 0.79 | ELAVL1 (0.79) | ELAVL1MEN1KMT2AMAPTHTR6 | |
| SCHEMBL22130653 | 0.78 | ELAVL1 (0.58) | ELAVL1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL22130693 | 0.78 | ELAVL1 (0.81) | ELAVL1MAPTHTR6ALDH1A1SMN1; SMN2 | |
| SCHEMBL22130634 | 0.76 | ELAVL1 (0.83) | ELAVL1HTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | UNIVERSITA' DEGLI STUDI DI TRENTO (IT) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | AZI2, TPMT, TYMS | ELAVL1 2765/4885MEN1 3554/4885KMT2A 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.